GlassScriptPhysician profile
Robert Arden Valice
NPI 1346284759
$175,210.04
in general payments reported to CMS, 2019-2025
3 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $717 · 2021: $41K · 2022: $55K · 2023: $28K · 2024: $25K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $78K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $78,373.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $174,472.65 | 2021-2025 | |
| Medtronic Vascular, INC. | $716.90 | 2020 | |
| Cashflow Solutions, LLC | $20.49 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Valice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.